Athero Review - Issue 2/2021
Editorial
63
Reviews
67
Hypolipidemic treatment improves the prognosis of diabetics. Why do we use it so modestly?
Richard Češka, Jiří Šilar
73
76
SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure
Josef Kořínek, Miloš Dobiáš
84
The LDL number is alive!
Richard Češka
90
95
Residual inflammatory cardiovascular risk – diagnostic and therapeutic challenge
Ján Murín, Jozef Bulas, Martin Wawruch, Udovít Gašpar
99
103
New alirocumab dosing regimen: 300 mg every 4 weeks
Petr Ošťádal
Announcements
110
Athero Review
2021 Issue 2
Most read in this issue
- Physical activity in treatment and prevention with a focus on risk factors for cardiovascular disease
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure
- Insulin resistance and its targeting in clinical practice
- The LDL number is alive!